JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Herpes zoster and dementia : more evidences for a causal link	639
Gene and genetic therapies in Alzheimer’s disease and other dementias	147
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	139
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	121
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	104
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	93
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	89
Lecanemab over a two-year duration: Key insights from a regional specialty medical center	84
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	74
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	72
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	64
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	62
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study	57
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	52
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	48
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	44
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	44
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	42
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status	42
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	41
Structural social factors modify the association between Alzheimer’s pathology and cognitive function	41
Introduction to the Special Issue on the A4 Study	40
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	39
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	37
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	35

Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	34
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	34
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	33
Informal care for people with dementia in Europe	32
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	31
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	31
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	31
Content	31
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	30
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	30
Donanemab: Appropriate use recommendations	29
Editorial Board	27
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	27
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	26
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	25
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	25
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	24
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	24
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease	24
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	24
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	23
Multi-modal data analysis for early detection of alzheimer’s disease and related dementias	23
Living arrangements and cognitive resilience in aging: unraveling distinct pathways through plasma biomarkers	23
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	22
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	22
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	22
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	22
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	22
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	22
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	22
Treatments for Alzheimer’s and the declaration of Helsinki	22
What can artificial intelligence bring to Alzheimer’s disease clinical trials? A first perspective	21
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	21
Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension	21
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	21
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	21
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	20
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	20
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	20
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	20
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study	20
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	19
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	19
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	19
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	19
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	19
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	19
Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults	19
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	19
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	19

Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	18
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	18
Clarifying what BP Predicts: Commentary on CSF Aβ42/40, p-tau181, and centiloid in unimpaired populations	18
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	18
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	18
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	18
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	17
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	17
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	17
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	17
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	17
Association of life’s simple 7 with cognitive function in a multi-ethnic cohort	17
Predicting cognitive decline: Comparative analysis of ANU-ADRI, CAIDE, CogDrisk, LIBRA, LIBRA2, UKBDRS and Lancet based dementia risk scores in the HUNT study	17
Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease	17
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	16
Amyloid pathology and modifiable risk factors in cognitive decline among cognitively unimpaired older adults	16
Hypolipidemics reduce the rate of Alzheimer's disease development and dementia progression: A cohort study linked with genetic and neuropathological analyses	16
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	16
Lipid-lowering regimens in Alzheimer’s disease dementia: small effects with potential long-term benefit	16
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	16
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	15
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	15
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease	15
Editorial Board	15
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	15
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	15
Iron dysregulation in cerebral small vessel disease: A quantitative susceptibility mapping study revealing spatial patterns and cognitive predictive value	15
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	15
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	15
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	15
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	15
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	14
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	14
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	14
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	14
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	14
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	13
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	13
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	13
Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease	13
Artificial intelligence and the acceleration of Alzheimer’s research - From promise to practice	13
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	13
Corrigendum to “Systematic post-translational modification genome wide identifies therapeutic targets for Alzheimer’s disease: evidence from multi-cohort analysis” [J Prev Alzheimer Dis, 13 (2026) 100	13
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	13
Editorial Board	13
Integrative SMR prioritizes oxidative stress–related regulatory genes for Alzheimer’s disease with brain-tissue validation	13
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	13
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	13
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	13
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	13
Sociodemographic differences in dementia prevention knowledge in Germany: Implications for targeted health communication	13
Tau in Alzheimer's disease: Shaping the future patient journey	13
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	12
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	12
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	12
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	12
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	12
AI models, bias and data sharing efforts to tackle Alzheimer's disease and related dementias	12
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	12
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	12
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	12
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	12
Alzheimer’s disease prevention by flavonols and their analogs	12
Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice	12
Add-on combination therapy with monoclonal antibodies: Implications for drug development	12
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	12
Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	12
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	12
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	12
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	12
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	12
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	12
It’s time to address the recruitment bottleneck	12
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic	12
Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer’s disease	11
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	11
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	11
The Future is Now: Advancing Blood-Based Markers	11
Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	11
Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial	11

Content	11
The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study	11
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	11
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	11
Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI	11
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	11
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	11
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	11
Association between plant-based diets and incident dementia: results from prospective cohort studies and a meta-analysis	11
Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study	11
The Dawn of a New Era of Alzheimer's Research and Drug Development	10
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	10
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	10
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	10
Spatial amyloid–informed multimodal brain age as an early marker of Alzheimer’s-related vulnerability and risk stratification	10
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	10
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	10
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	10
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	10
Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial	10
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	10
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	10
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration	10
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	10
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	10
Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort	9
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	9
Evaluating evidence-based recruitment strategies for Alzheimer’s disease and related dementias clinical trial research: A literature review	9
The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease	9
Early-Onset Type 2 Diabetes and Risk of Dementia	9
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	9
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	9
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	9
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	9
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	9
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	9
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	9
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	9
Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer’s disease	9
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	9
Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review	9
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	9
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	9
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	9
Microglial activation states and their implications for Alzheimer's Disease	9
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	9
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	9
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	9
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	9
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	9
Editorial Board	8
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults	8
Advancing nutritional strategies for brain health: Reconciling epidemiologic findings with clinical applicability	8
Eligibility for donanemab trial in a population-based study of cognitive aging	8
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress	8
“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies	8
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials	8
Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies	8
Appropriate Use Recommendations for Lecanemab	8
Dietary Cholesterol and Dementia Risk	8
Hypnotics and Incident Dementia: A Risk Assessment	8
Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies	8
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease	8
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease	8
Medical risk factors, ApoE haplotype, and Alzheimer’s disease: a large-scale analysis	8
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies	8
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography	8
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial	8
Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication	8
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges	8
Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool	8
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial	8
Barriers and facilitators to recruitment, engagement, and retention of underrepresented populations in dementia prevention research: a scoping review	8
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study	8
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis	8
Brain health PRO/santé cerveau PRO: The development of a web-based program for dementia literacy and risk factor reduction	8
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	8
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	8
Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study	8
Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial	8
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia	8
Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	8
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment	8
Response to letter to the editor: “Reevaluating the Neuroprotective promise of dietary nitrate: Commentary on Rajendra et al. (2025)	7
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease	7
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease	7
Editorial Board	7
Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies	7
Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes	7
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report	7
What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?	7
Association of the cumulative modified life’s Essential 8 score with cognitive change: Results from two longitudinal cohorts	7
Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD	7
A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's D	7
Content	7